Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer

Cancer

Volumn 110, Issue 4, 2007, Pages 845-853

  Gregorc, Vanesa ^a   Spreafico, Anna ^b   Floriani, Irene ^c   Colombo, Barbara ^a   Ludovini, Vienna ^b   Pistola, Lorenza ^b   Bellezza, Guido ^b   Viganò, Maria Grazia ^a   Villa, Eugenio ^a   Corti, Angelo ^a,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b POLICLINICO MONTELUCE   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Research Unit of Molecular Neuroscience   (Italy)

Author keywords

Chromogranin A; Nonsmall cell lung cancer; Performance status; Survival; Tumor necrosis factor

Indexed keywords

CHROMOGRANIN A; CISPLATIN; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LIVER FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOGRANIN A; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TREATMENT OUTCOME;

EID: 34547873893     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22856     Document Type: Article

References (38)

1. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 1992;49:497-528.
2. Rosa P, Gerdes HH. The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocr Invest. 1994;17:207-225.
3. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
4. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med. 1984;311:764-770.
5. Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med. 1989;320:444-447.
6. Deftos LJ. Chromogranin A; its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181-187.
7. Bofin AM, Qvigstad G, Waldum C, et al. Neuroendocrine differentiation in carcinoma of the breast. Tyramide signal amplification discloses chromogranin A-positive tumour cells in more breast tumours than previously realized. APMIS. 2002;110:658-664.
8. Kimura N. Chromogranins in non-endocrine tumours. Adv Exp Med Biol. 2000;482:369-373.
9. Kimura N, Yoshida R, Shiraishi S, et al. Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma. Endocr Pathol. 2002;13:117-122.
10. Young RH, Srigley JR, Amin MB, et al. Carcinoma of the prostate gland (excluding unusual variants and secondary carcinomas). In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. Volume 28. 3rd series ed. Washington, DC: Armed Forces Institute of Pathology; 2000:111-216.
11. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992-2000.
12. Graziano SL, Tatum AH, Newman NB, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994;54:2908-2913.
13. Ziegler MG, Kennedy B, Morrissey E, et al. Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure. Kidney Int. 1990;37:1357-1362.
14. Syversen U, Ramstad H, Gamme K, et al. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol. 2004;39:969-973.
15. Borch K, Stridsberg M, Burman P et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32:198-202.
16. Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150:299-303.
17. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor alpha in heart failure. Adv Exp Med Biol. 2000;482:351-359.
18. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23:967-974.
19. Cubeddu LX, O'Connor DT, Hoffmann I, et al. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Br J Cancer. 1995;72:1033-1038.
20. Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncol. 1995;13:681-687.
21. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
22. Corti A, Longhi R, Gasparri A, et al. Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Eur J Biochem. 1996;235:275-280.
23. Sobol RE, O'Connor DT, Addison J, et al. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med. 1986;105:698-700.
24. Nisman B, Heching N, Biran H, et al. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol. 2006;27:8-16.
25. Corti A, Ferrero E. Chromogranin A: more than a marker for tumor diagnosis and prognosis. Curr Med Chem-Immun Endoc & Metab Agents. 2004;4:161-167.
26. Angelsen A, Syversen U, Haugen OA, et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate. 1997;30:1-6.
27. Schleusener JT, Tazelaar HD, Jung SH, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer. 1996;77:1284-1291.
28. Graziano SL, Tatum A, Herndon JE 2nd, et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non- small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 2001;33:115-123.
29. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer. 1993;10:209-219.
30. Gajra A, Tatum AH, Newman N, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 2002;36:159-165.
31. Colombo B, Curnis F, Foglieni C, et al. Chromogranin a expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res. 2002;62:941-946.
32. Waterston A, Bower M. TNF and cancer: good or bad. Cancer Ther. 2004;2:131-148.
33. Fiers W Biologic therapy with TNF: preclinical studies. In: De Vita V, Hellman S, Rosenberg S, eds. Biologic Therapy of Cancer: Principles and Practice. Philadelphia: J.B. Lippincott; 1995:295-327.
34. Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immunol Immunother. 2006;6:6.
35. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314-320.
36. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565-573.
37. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7:231-240.
38. Ferrero E, Scabini S, Magni E, et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J. 2004;20:20.